AbSci is a pioneering brand that offers a cutting-edge AI-integrated platform for biological drug discovery and cell line development, revolutionizing the field of medicine. With a mission to create better biologics for patients, faster, AbSci utilizes an innovative generative AI approach to design antibodies from scratch, without relying on existing databases. These novel candidates can then be experimentally validated in AbSci's wet lab, eliminating the time-consuming step of lead optimization.

By leveraging the power of generative AI, AbSci is transforming traditional drug discovery by significantly reducing preclinical development timelines and increasing success rates. Partnering with drugmakers, AbSci enables de novo design, lead optimization, target identification, and antibody-drug conjugate (ADC) development, leading to tailored therapeutics with improved target binding, manufacturability, lower immunogenicity, and shorter development times. With their Integrated Drug Creation™ platform, AbSci combines AI and synthetic biology, empowering the rapid creation and validation of innovative biologic-based drugs.

This groundbreaking technology has garnered recognition and investment from industry leaders, highlighting its potential to disrupt the biopharmaceutical landscape. Overall, AbSci is dedicated to transforming drug creation and bringing life-changing treatments to patients worldwide